Contact Us
Drug Search Results
More Filters [+]

Terlipressin

Alternative Names: terlipressin, glypressin, terlivaz
Latest Update: 2024-12-09
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: V1 Agonist,V2 Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Hepatorenal Syndrome

Known Adverse Events: Abdominal Pain | Pain Unspecified | Dyspnea | Respiratory Insufficiency | Diarrhea

Company: Mallinckrodt
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Terlipressin

Countries in Clinic: France, India, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Edema, Cardiac|Esophageal and Gastric Varices|Gas Gangrene|Hemoptysis|Hypertension, Portal|Hypertension, Pulmonary|Hyponatremia|Liver Cirrhosis|Myocardial Ischemia|Pulmonary Edema

Phase 2: Acute Kidney Injury|Hepatorenal Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ACTIVE

P3

Recruiting

Hemoptysis

2025-12-31

PHIN-001

P1

Recruiting

Liver Cirrhosis

2025-10-31

R2R01-HRS-201

P2

Recruiting

Acute Kidney Injury|Hepatorenal Syndrome

2024-12-01

TERLEVL

P3

Not yet recruiting

Hypertension, Pulmonary|Gas Gangrene|Pulmonary Edema|Hyponatremia|Liver Cirrhosis|Esophageal and Gastric Varices|Hypertension, Portal|Myocardial Ischemia|Edema, Cardiac

2024-08-01

Recent News Events

Date

Type

Title

11/20/2024

News Article

 BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

11/18/2024

News Article

 Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

10/30/2024

News Article

 Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

10/29/2024

News Article

 BioVie Inc. Announces Closing of Registered Direct Offering

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions